SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zenotech Laboratorie - Quaterly Results

30 Oct 2023 Evaluate
A fair growth of 12.03% in the revenue at Rs. 115.28 millions was reported in the September 2023 quarter as compared to Rs. 102.90 millions during year-ago period.Profit after tax improved marginally to Rs. 28.33  millions for the quarter ended September 2023 from Rs. 27.66 millions of corresponding previous quarter.Operating profit for the quarter ended September 2023 rose to 57.04 millions as compared to 56.55 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 115.28 102.90 12.03 207.84 226.56 -8.26 424.24 365.65 16.02
Other Income 1.93 6.47 -70.17 3.94 6.95 -43.31 10.84 6.29 72.34
PBIDT 57.04 56.55 0.87 95.71 127.92 -25.18 217.87 180.90 20.44
Interest 0.00 0.00 0.00 0.00 1.12 0.00 1.12 12.15 -90.78
PBDT 57.04 56.55 0.87 95.71 126.80 -24.52 216.75 168.75 28.44
Depreciation 18.07 18.05 0.11 36.08 35.91 0.47 71.73 69.74 2.85
PBT 38.97 38.50 1.22 59.63 90.89 -34.39 145.02 99.01 46.47
TAX 10.64 10.84 -1.85 16.86 25.52 -33.93 29.17 -122.75 -123.76
Deferred Tax 10.64 10.84 -1.85 16.86 25.52 -33.93 29.17 -122.75 -123.76
PAT 28.33 27.66 2.42 42.77 65.37 -34.57 115.85 221.76 -47.76
Equity 610.31 610.31 0.00 610.31 610.31 0.00 610.31 610.31 0.00
PBIDTM(%) 49.48 54.96 -9.97 46.05 56.46 -18.44 51.36 49.47 3.80

Zenotech Laboratorie Share Price

45.96 -0.94 (-2.00%)
24-Apr-2026 13:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1614.70
Dr. Reddys Lab 1328.10
Cipla 1300.90
Zydus Lifesciences 930.55
Lupin 2281.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×